Iron metabolism in rhEPO-treated hemodialysis patients

Clinical Nephrology

Volumn 53, Issue SUPPL. 1, 2000, Pages

  Schaefer, R M ^a,b   Bahner, U ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Erythropoietin hemodialysis; Iron

Indexed keywords

FERRITIN; IRON; IRON DEXTRAN; IRON SACCHARATE; PROTOPORPHYRIN ZINC; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DRUG EFFICACY; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; IRON METABOLISM; IRON THERAPY; PATHOPHYSIOLOGY;

ENZYME INHIBITORS; ERYTHROCYTES; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HUMANS; IRON; PROTOPORPHYRINS; RENAL DIALYSIS; TRANSFERRIN;

EID: 0034012020     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Allegro V.MengozziG, l'asile A 1991 Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57: 175-182
2. Baldus M, Salopek S. Müller M et al 1996 Experience with ZnPP as marker of endogenous iron availability in chronic hemodialysis patients. Nephrol Dial Transplant 11:486-491
3. Boelaert JR, Cantinieaux BF. Hariga CF, Fondu PG 1983 Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 5: 504-507
4. Braun J, Hammerschmidt M. Schreiber M, Heidler R, Hörl WH Is ZnPP an indicator of iron-deficient erythropoiesis in maintenance hemodialysis patients? Nephrol Dial Transplant 11: 492-497
5. Canlinieaux B, BoelaertJ, Hariga C, Fondu P 1988 Impaired neutrophil defense against Yersinia enterocotitica in patients with iron overload who are undergoing dialysis. J Lab Clin Med 111: 524-528
6. Eschbach JW, Cook JD, Scribner BH, Finch CA 1977 Iron balance in hemodialysis patients. Ann Intern Med 87:710-713
7. Fishbone S. Ungtireanti VD. Maeseka JK 1996 The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28: 529-534
8. Fishbone S, Galgano C, Langley RC Jr., Canfleld W, Maeseka JK 1997 Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52:217-222
9. Flament J, Goldmann M, Walerlol Y, Dupant E, ffybran J, Vanhenveghem JL 1986 Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 25: 227-230
10. HamstraRD, Block MH, Schocket AL 1980 Intravenous iron dextran in clinical medicine. JAMA 243: 1726-1731
11. Hastka J, Laserre JJ, Schwarzbeck A, Hehlman R, Strauch M 1991 ZnPP als Alternative zu Ferritin bei der Steuerung der Eisensubstitution Erythropoietin-bedürftiger Dialysepatienten [ZnPP äs an alternative to ferritin in guiding iron substitution in dialysis patients requiring erythropoietin]. Nieren-Hochdruckkrkh 20: 697-700
12. Hôrl WH, Cavill I, Macdougall 1C, Schaefer RM, Sunder-Plassmann G 1996 How to diagnose and correct iron deficiency during r-I luEPO therapy- a consensus report. Nephrol Dial Transplant 11:246-250
13. Kalandar-Zadeh K, HöJJken B, Wünsch H, Fink H, Kleiner M, LuftFC 1995 Diagnosis of iron deficiency anemia in renal failure patients during the posterythropoietin era Am J Kidney Dis 26: 292-299
14. LipschitzDA, Cook JD, Finch CA 1974AcIinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 290: 1213-1216
15. Macdougall 1C, Mutton RD. Cavilll, Coles GA, llllliana JD 1990 Treating renal anemia with r-HuEPO: practical guidelines and a clinical algorithm. Br Med J 300: 655-659
16. Macdougall 1C. Cavill I, HulmeBet al 1992 Detection of functional iron deficiency during r-Hu-EPO treatment: a new approach. Br Med J 304: 225-226
17. Macdougall 1C, Tucker B, Thompson J, Tomson CRV, Baker LR1, Raine AEG 1996 A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699
18. Macdougall 1C, Chandler G, Armstrong A, Breen C, Harchowal J, Cavill I 1997 Characterization of iron availability from 3 different intravenous iron preparations in dialysis patients. J Am Soc Nephrol 8:221 A
19. Schaefer RM, Schaefer L1995 The hypochromic red cell: a new parameter for the monitoring of iron supplementation during r-HuEPO therapy. J Perinat Med 23, 83-88
20. Silverberg DS, Blum M, Peer G, Kaplan E, laina A 1996 Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417
21. Sunder-Plassmann G, Hörl WH 1996 Safety of intravenous injection of iron saccharate in hemodialysis patients. Nephrol Dial Transplant 11: 1797-1802
22. Zonen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong RMT Oversaturation of transferrin after intravenous ferric gluconate (Ferrlecit) in hemodialysis patients. Nephrol Dial Transplant 11: 820-824